Oxaliplatin

Oxaliplatin was purchased from Sigma (USA) and dissolved in 5% glucose/H₂O as a stock solution of 1 mg/ml as a previous study reported.^{14 (link)} Rats were intraperitoneally administered Oxaliplatin at 4 mg/kg once per day for five consecutive days to induce mechanical allodynia. The control rats received an intraperitoneal injection of an equivalent volume of 5% glucose/H₂O. Intrathecal injection of the neutralizing antibody against CXCL12 (8 µg, 10 μl; Torrey Pines Biolabs, Secaucus, NJ), neutralizing antibody against TNF-α (10 µg, 10 μl; R&D systems, Minneapolis, MN), a isotype IgG (8 µg, 10 μl; Sigma, Bellevue, WA), the IL-1 receptor antagonist (IL-1ra; 50 µg, 10 μl; R&D Systems, Minneapolis, MN), a STAT3 inhibitor S3I-201 (100 µg, 10 μl; Selleckchem, Houston, TX), scramble siRNA (1 nmol, 10 μl; Ribobio, China), or CXCL12 small interfering RNA (siRNA; 1 nmol, 10 μl; Ribobio, China) for consecutive 10 days was performed 30 min before Oxaliplatin administration. In addition, recombinant rat CXCL12 (2 µg, 10 μl; Signalway Antibody, College Park, USA) were intrathecally injected for consecutive 10 days.

Oxaliplatin was purchased from Sigma (USA) and dissolved in 5% glucose/H₂O as a stock solution of 1 mg/ml, as reported in a previous study.^{8 (link)} Rats were intraperitoneally administered Oxaliplatin at 4 mg/kg once per day for five consecutive days to induce thermal hyperalgesia. The control rats were intraperitoneally injected with an equivalent volume of 5% glucose/H₂O. Intrathecal injection of isotype IgG (10 μg in 10 μl, R&D system, USA), a neutralizing antibody against CX3CL1 (10 μg in 10 μl, Torrey Pines Bio Labs, USA), ammonium pyrrolidine dithiocarbamate (PDTC; 200 ng in 10 μl, Sigma, USA), scramble siRNA (50 μg in 15 μl, Ribobio, China), or NF-κB p65 small interfering RNA (siRNA; 50 μg in 15 μl, Ribobio, China) was performed 30 min before Oxaliplatin administration.